Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 52,87 € (+180,18%). Mediana wynosi 58,80 € (+211,61%).
| Kupuj |
32 |
| Trzymaj |
6 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Uniqure rises after William Blair 'outperform' and progress on AMT-130
Uniqure shares gained about 2.4% in premarket trading after William Blair initiated coverage with an “Outperform” rating. Analysts are broadly optimistic (11 buy, 1 hold), and agreement with the FDA on an accelerated approval pathway for AMT-130 has boosted investor sentiment. Uniqure also benefited from a solid cash position and an amended credit facility with Hercules Capital; the recent roughly 175% rally from the 52-week low is seen as company-specific. » Więcej na de.investing.com
uniQure receives FDA confirmation for accelerated BLA pathway for AMT-130 and reports sales increase
uniQure said the FDA confirmed in writing after a Type B meeting that a BLA filing for Huntington’s therapy AMT-130 is appropriate under an accelerated pathway based on existing clinical data. The company beat revenue consensus in Q2 with $5.84m, but reported a higher net loss per share due to increased selling, general and administrative expenses. uniQure plans to file regulatory applications in the US and the UK in Q3 2026, strengthened its balance sheet with a $259m capital raise and extended its cash runway to 2030. The announcements pushed the stock about 6.3% higher in premarket trading. » Więcej na de.investing.com
UniQure beats revenue estimate and secures $259 million financing through 2030
UniQure reported Q2 revenue of $5.80 million, exceeding the consensus expectation of $5.47 million, while net loss widened due to higher selling, general and administrative and non‑operating expenses. The revenue increase was driven by higher license income; rising personnel and contractor costs reflect preparations for potential product launches. Through a follow‑on placement, UniQure raised $259 million and says this secures liquidity through 2030; regulatory filings for AMT‑130 are planned for Q3 2026 and topline four‑year data are expected in September 2026. » Więcej na de.investing.com
uniQure presents mixed Phase I/IIa data on epilepsy gene therapy AMT‑260
In the low‑dose cohort (1x10^12 gc/mL) of the Phase I/IIa study, three of six patients showed a 79–100% reduction in disabling seizures in months 4–6; the other three patients had changes of −33% to +36% versus baseline. No serious adverse events have been reported to date; adverse events were mild to moderate, headaches were most common, and no immunosuppression was required. Recruitment of a higher‑dose cohort (3x10^12 gc/mL) is ongoing, with completion expected mid‑2026 and updated study data planned for H1 2027. The study announcement drove the share price up 67.9% to 46.29 USD and lifted market capitalization to 2.92 billion USD; an analysis by InvestingPro currently rates the stock as overvalued. » Więcej na de.investing.com
UniQure to seek FDA approval for Huntington's gene therapy after agency reverses stance
UniQure plans to submit an FDA application in Q3 for its experimental gene therapy for Huntington's disease after a recent meeting indicated a three-year analysis from a Phase 1/2 study could support accelerated approval. The FDA previously questioned the sufficiency of UniQure's data and had asked for a placebo-controlled trial, but now agrees the company can use external control data and wants to align on a post-approval confirmatory study comparing the treatment to standard of care. UniQure expects to finalize the confirmatory trial design before submitting its application. » Więcej na cnbc.com
Historyczne dywidendy Dywidendy
Wszystkie wskaźniki dywidendowe Wszystkie wskaźnikiDane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 4,59 mln | 45,46% |
| Zysk brutto | 4,38 mln | 55,58% |
| Zysk netto | -54,05 mln | 21,24% |
| EBITDA | -35,77 mln | 18,57% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 1,3 mld € |
Liczba akcji | 70,14 mln |
Maksimum/minimum z 52 tygodni | 47,15 € - 7,96 € |
| Dywidendy | Nie |
Beta | 0,94 |
C/Z (PE Ratio) | -5,73 |
PEG (PEG Ratio) | -0,40 |
C/WK (PB Ratio) | 4,82 |
C/S (PS Ratio) | 70,60 |
Profil spółki
uniQure N.V., firma zajmująca się terapią genową, prowadzi prace nad leczeniem pacjentów cierpiących na choroby genetyczne i inne poważne schorzenia. Jej głównym programem jest Etranacogene dezaparvovec (AMT-061), który znajduje się w pivotalnym badaniu fazy III HOPE-B dotyczącym leczenia hemofilii B. Firma rozwija również AMT-130, terapię genową będącą w badaniu klinicznym fazy I/II w leczeniu choroby Huntingtona; AMT-060, który jest w badaniu klinicznym fazy I/II w leczeniu hemofilii B; AMT-210, kandydat na produkt do leczenia choroby Parkinsona; AMT-260 do leczenia padaczki skroniowej; AMT-240, przedklinicznego kandydata na produkt do leczenia autosomalnie dominującej choroby Alzheimera; oraz AMT-161 do leczenia stwardnienia zanikowego bocznego. uniQure N.V. została założona w 1998 roku i ma siedzibę w Amsterdamie w Holandii.
| Nazwa | uniQure |
| CEO | Matthew C. Kapusta |
| Siedziba | Amsterdam,
nh Holandia |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 05.02.2014 |
| Pracownicy | 221 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | QURE |
London Stock Exchange | 0EE0.L |
Frankfurt | UQ1.F |
London | 0EE0.L |
SIX | UQ1.SW |